Rewalk Robotics (NASDAQ:RWLK) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research lowered shares of Rewalk Robotics (NASDAQ:RWLK) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports.

According to Zacks, “ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company’s exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel. “

Several other brokerages also recently commented on RWLK. ValuEngine raised shares of Rewalk Robotics from a hold rating to a buy rating in a report on Tuesday, July 2nd. HC Wainwright raised shares of Rewalk Robotics from a neutral rating to a buy rating and raised their price target for the company from $4.00 to $9.00 in a report on Monday, June 17th.

RWLK opened at $3.24 on Friday. The company has a 50 day moving average of $3.97 and a 200 day moving average of $2.82. The company has a market cap of $24.64 million, a PE ratio of -0.22 and a beta of 1.54. Rewalk Robotics has a 12 month low of $2.46 and a 12 month high of $27.00. The company has a current ratio of 3.41, a quick ratio of 1.50 and a debt-to-equity ratio of 0.33.

Rewalk Robotics (NASDAQ:RWLK) last released its quarterly earnings data on Thursday, August 8th. The medical device company reported ($0.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.39). Rewalk Robotics had a negative return on equity of 452.23% and a negative net margin of 320.80%. The business had revenue of $0.88 million during the quarter, compared to the consensus estimate of $2.48 million. Research analysts forecast that Rewalk Robotics will post -2.62 earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the business. Gabelli Funds LLC bought a new position in Rewalk Robotics in the 2nd quarter valued at $118,000. FNY Investment Advisers LLC boosted its holdings in Rewalk Robotics by 4,595.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 75,120 shares of the medical device company’s stock valued at $326,000 after purchasing an additional 73,520 shares during the period. Finally, Geode Capital Management LLC bought a new position in Rewalk Robotics in the 4th quarter valued at $49,000.

About Rewalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.

See Also: How does equity income fit into an investing strategy?

Get a free copy of the Zacks research report on Rewalk Robotics (RWLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bank of New York Mellon Corp Purchases 65,188 Shares of VANGUARD WHITEH/EMERGING MKT GOVT B
Bank of New York Mellon Corp Purchases 65,188 Shares of VANGUARD WHITEH/EMERGING MKT GOVT B
SunOpta  Stock Rating Lowered by Zacks Investment Research
SunOpta Stock Rating Lowered by Zacks Investment Research
Carrols Restaurant Group  Stock Rating Lowered by Zacks Investment Research
Carrols Restaurant Group Stock Rating Lowered by Zacks Investment Research
Seagate Technology  PT Raised to $48.00
Seagate Technology PT Raised to $48.00
Lendingtree  Upgraded at BidaskClub
Lendingtree Upgraded at BidaskClub
Chardan Capital Lowers Tocagen  to Neutral
Chardan Capital Lowers Tocagen to Neutral


© 2006-2019 Ticker Report